

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Original) A stable protein preparation, wherein the preparation comprises one or more stabilisers selected from the group consisting of non-polar and basic amino acids and wherein the preparation has a pH of 4.2 to 5.4.

2. (Original) The preparation of claim 1, wherein the one or more stabilisers are selected from the group consisting of histidine, arginine, lysine, ornithine, isoleucine, valine, methionine, glycine and proline.

3. (Currently Amended) The preparation of ~~claims 1 or~~ claim 2, wherein the stabiliser is proline.

4. (Original) The preparation of claim 3, wherein proline is L-proline.

5. (Currently Amended) The preparation of claim 1 ~~any one of the preceding claims~~, wherein said preparation it has a pH of 4.5 to 5.2.

6. (Currently Amended) The preparation of claim 5, wherein said preparation it has a pH of 4.6 to 5.0.

7. (Currently Amended) The preparation of claim 1 ~~any one of the preceding claims~~, wherein said preparation ~~it~~ comprises the one or more stabilisers ~~stabiliser~~ at a final concentration of at least 0.2 M.

8. (Currently Amended) The preparation of claim 7, wherein said preparation ~~it~~ comprises the one or more stabilisers ~~stabiliser~~ at a final concentration of 0.2 to 0.4 M.

9. (Currently Amended) The preparation of claim 8, wherein said preparation ~~it~~ comprises the one or more stabilisers ~~stabiliser~~ at a final concentration of 0.25 M.

10. (Currently Amended) The preparation of claim 1 ~~any one of the preceding claims~~, wherein ~~its~~ the protein concentration of said preparation is from 5 to 25% w/v.

11. (Currently Amended) The preparation of claim 10, wherein ~~its~~ the protein concentration of said preparation is from 15 to 20% w/v for subcutaneous administration.

12. (Currently Amended) The preparation of claim 10, wherein ~~its~~ the protein concentration of said preparation is from 6 to 15% w/v, for intravenous administration.

13. (Currently Amended) The preparation of claim 12, wherein ~~its~~ the protein concentration of said preparation is from 8 to 12% w/v.

14. (Currently Amended) The preparation of claim 1 ~~any one of the preceding claims~~, wherein it said preparation is an immunoglobulin preparation.

15. (Currently Amended) The preparation of claim 14 ~~any one of the preceding claims~~, wherein it said preparation is an IgG, IgA or IgM preparation.

16. (Currently Amended) A pharmaceutical composition comprising the protein preparation of ~~one of the preceding claims~~ claim 14 and pharmaceutically acceptable additives.

17. (Currently Amended) The pharmaceutical composition of claim 14 ~~16~~, wherein it ~~comprises the immunoglobulin preparation of any one of claims 11 to 15 for~~ a dosage of said composition is 0.2 to 2.0g immunoglobulin per kg bodyweight per day.

18. (Currently Amended) A method of stabilising protein preparations, ~~in particular immunoglobulin preparations~~, comprising providing an aqueous protein solution and adding one or more stabilisers selected from the group consisting of basic and non-polar amino acids, wherein the pH of the solution is adjusted to a pH of about 4.2 to 5.4.

19. (Currently Amended) The method of claim 18, wherein the one or more stabilisers ~~stabiliser~~ is selected from the group consisting of histidine, arginine, lysine, ornithine, isoleucine, valine, methionine and proline.

20. (Currently Amended) The method of claim 18 ~~or 19~~, wherein the pH is adjusted to 4.8. •

21. (Currently Amended) The method of ~~any one of claims~~ claim 18 ~~to 20~~, wherein the final ~~stabiliser~~ concentration of the one or more stabilisers is adjusted to 0.2 to 0.4 M.

22. (New) The method of claim 18, wherein the protein preparation is an immunoglobulin preparation.

23. (New) A pharmaceutical composition comprising the protein preparation of claim 1 and pharmaceutically acceptable additives.